Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling

Kerdivel, G ; Chesnais, V ; Becht, E ; Toma, A ; Cagnard, N ; Dumont, F ; Rousseau, A ; Fenaux, P ; Chevret, S ; Chapuis, N ; Boeva, V ; Fridman, W H ; Fontenay, M ; Kosmider, O

Leukemia, 2018-02, Vol.32 (2), p.558-562 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível